2022
Public engagement highlights
Annual overview of the involvement of patients and healthcare professionals (HCP) in the work of EMA

In 2022, as COVID-19 restrictions eased, EMA met patient and HCP representatives face-to-face for the first time since 2019. Priorities to enhance the collection and use of patient experience data for medicines development and regulation were agreed with stakeholders. Experience on patients’ early dialogue with CHMP was analysed and will continue, expanding to HCP. A published study highlighted the impact of patient contribution to scientific advice procedures. Patient and HCP representatives joined the Medicines Shortages Steering Group (MSSG). The end of the year saw the start of the next mandate of the PCWP/HCPWP and the election of new co-chairs.

Stakeholder involvement in medicine*

### Patient contribution to EMA’s work

<table>
<thead>
<tr>
<th>Patient membership numbers</th>
<th>57</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMA Management Board</td>
<td>2</td>
</tr>
<tr>
<td>Scientific committees</td>
<td>12</td>
</tr>
<tr>
<td>Patients’ and Consumers’ Working Party</td>
<td>43</td>
</tr>
<tr>
<td>Active patient experts</td>
<td>80</td>
</tr>
<tr>
<td>PCO eligible organisations</td>
<td>42</td>
</tr>
</tbody>
</table>

### HCP contribution to EMA’s work

<table>
<thead>
<tr>
<th>HCP membership numbers</th>
<th>57</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMA Management Board</td>
<td>2</td>
</tr>
<tr>
<td>Scientific committees</td>
<td>12</td>
</tr>
<tr>
<td>Patients’ and Consumers’ Working Party</td>
<td>42</td>
</tr>
<tr>
<td>Active HCP experts</td>
<td>140</td>
</tr>
<tr>
<td>HCP eligible organisations</td>
<td>39</td>
</tr>
</tbody>
</table>

* In 2022, the Public and Stakeholder engagement department changed its reporting methodology to include the number of eligible organisations and corresponding experts in the database.

Key events

**Multistakeholder workshop on EMA’s Extended Mandate**

Patients and HCP representatives joined this event informing all stakeholders of the regulation reinforcing EMA’s role in public health emergencies, monitoring and mitigating shortages and coordinating expert panels on high-risk medical devices and in vitro diagnostics.

View event summary

**Multistakeholder event on patient experience data**

This workshop gathered input from patients, consumers, healthcare professionals, academia, regulators, health technology assessment bodies and industry on what constitutes ‘Patient Experience Data’ and how to best collect and use this data to ensure the patient perspective is systematically captured in medicine development and evaluation.

View event summary

Queries by stakeholder

- Patients: 13%
- HCPs: 10%
- Others: 78%

Total number queries: **2374**
Overall satisfaction: **68%**

Common topics

- COVID-19
- Availability
- Paediatrics
- Comirnaty
- Boosters
- Adverse drug reactions
- Valneva

Working party meetings

**March**

- ACT EU, Big Data, electronic product information, EMA’s extended mandate, Advanced Therapy Medicinal Products (ATMPs)

Access meeting documents

**June**

- New mandate and introduction to new members, Clinical Trials, COVID-19 updates, Big Data, creation of joint drafting group on the ICH E6 guidance on Good Clinical Practice

Access meeting documents

**September**

- Update on COVID-19, Big Data, use of EMA communications, election on new co-chairs

Access meeting documents

**November**

- Patient Experience Data, medicine shortages, HTA activities, antimicrobial resistance

Access meeting documents